Testing the drug paxalisib in people whose central nervous system lymphoma has come back
Official title: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called paxalisib in people with primary central nervous system lymphoma that came back or did not respond to earlier treatment.
Read our full plain-language summary
What the trial team says
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Key facts
- Registry number
- NCT04906096
- Stage of testing
- Phase 2
- Conditions studied
- Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
Where it is running
This trial lists 2 sites.
-
Massachusetts
- Brigham and Women's Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.